Keeping Future Options Open: Flexibility Across the EGFR Treatment Journey 

July 30, 2026

Reframing Treatment Conversations in EGFR+ NSCLC: Dr. Jonathan Riess and Dr. Susan Scott address misconceptions about chemotherapy in EGFR-mutant NSCLC, discussing how combination regimens from trials like FLAURA2 and MARIPOSA-2 compare to chemotherapy-free approaches, along with adverse event management, NCCN guideline updates, and strategies for shared treatment selection that keep future options open.